GW Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference
January 05 2021 - 7:30AM
GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the
Group), the world leader in the science, development, and
commercialization of cannabinoid prescription medicines, today
announced that Justin Gover, GW’s Chief Executive Officer, will
present a business update and 2021 outlook at the 39th Annual J.P.
Morgan Healthcare Conference on Tuesday, January 12, 2021 at 10:00
am PT (1:00 pm ET). In addition, a Q&A breakout session will
immediately follow the presentation at 10:20 am PT (1:20 pm ET).
A live audio webcast of the presentation will be
available through GW’s corporate website at www.gwpharm.com in the
Investors section under Events & Presentations. A replay will
be available soon after the live presentation.
About GW Pharmaceuticals plc and
Greenwich Biosciences, Inc.Founded in 1998, GW is a
biopharmaceutical company focused on discovering, developing and
commercializing novel therapeutics from its proprietary cannabinoid
product platform in a broad range of disease areas. The Company’s
lead product, EPIDIOLEX® (cannabidiol) oral solution, is
commercialized in the U.S. by its U.S. subsidiary Greenwich
Biosciences for the treatment of seizures associated with
Lennox-Gastaut syndrome (LGS), Dravet syndrome, or tuberous
sclerosis complex (TSC) in patients one year of age and older. This
product has received approval in the European Union under the
tradename EPIDYOLEX® for the adjunctive treatment of seizures
associated with LGS or Dravet syndrome in conjunction with clobazam
in patients two years and older and is under EMA review for the
treatment of TSC. The Company has a deep pipeline of additional
cannabinoid product candidates, in particular nabiximols, for which
the Company is advancing multiple late-stage clinical programs in
order to seek FDA approval in the treatment of spasticity
associated with multiple sclerosis and spinal cord injury. The
Company has additional cannabinoid product candidates in clinical
trials for autism and schizophrenia. For further information,
please visit www.gwpharm.com.
Enquiries:
GW Pharmaceuticals plc |
|
Scott Giacobello, Chief Financial Officer |
760 795 2200 |
|
|
U.S. Media |
|
Christy Curran |
615 414 8668 |
Sam Brown Inc. Healthcare Communications |
|
GW Pharmaceuticals (NASDAQ:GWPH)
Historical Stock Chart
From Jun 2024 to Jul 2024
GW Pharmaceuticals (NASDAQ:GWPH)
Historical Stock Chart
From Jul 2023 to Jul 2024